Prothena (NASDAQ:PRTA) announced its earnings results on Wednesday. The biotechnology company reported ($1.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.48) by $0.24, Briefing.com reports. The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.27 million. Prothena had a negative net margin of 562.19% and a negative return on equity of 34.40%. The company’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.41) EPS.
Prothena (PRTA) opened at $30.95 on Thursday. Prothena has a 12-month low of $27.19 and a 12-month high of $70.00. The stock has a market cap of $1,170.00, a PE ratio of -7.30 and a beta of 2.67.
PRTA has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $65.00 target price on shares of Prothena in a research note on Wednesday, December 20th. BidaskClub raised shares of Prothena from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 11th. ValuEngine lowered shares of Prothena from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. Oppenheimer set a $70.00 target price on shares of Prothena and gave the company a “buy” rating in a research note on Monday, December 4th. Finally, Wedbush lowered shares of Prothena from an “outperform” rating to a “neutral” rating and cut their target price for the company from $75.00 to $55.00 in a research note on Monday, November 20th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. Prothena has a consensus rating of “Buy” and a consensus price target of $75.58.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.